Acuta Capital Partners LLC Acquires 64,209 Shares of Liquidia Co. (NASDAQ:LQDA)

Acuta Capital Partners LLC boosted its stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 87.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 137,709 shares of the company's stock after buying an additional 64,209 shares during the quarter. Liquidia makes up approximately 1.6% of Acuta Capital Partners LLC's portfolio, making the stock its 20th largest holding. Acuta Capital Partners LLC owned about 0.16% of Liquidia worth $1,619,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. LM Advisors LLC bought a new position in Liquidia in the 4th quarter worth approximately $25,948,000. Invesco Ltd. lifted its holdings in shares of Liquidia by 2,675.0% in the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after buying an additional 674,940 shares in the last quarter. Mirabella Financial Services LLP bought a new position in shares of Liquidia in the fourth quarter valued at approximately $5,880,000. Eversept Partners LP increased its holdings in Liquidia by 314.1% during the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company's stock worth $6,719,000 after acquiring an additional 433,356 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Liquidia in the 4th quarter valued at $2,681,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $13.98 on Friday. The company has a market cap of $1.19 billion, a PE ratio of -8.58 and a beta of 0.23. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.81. The firm's 50 day moving average price is $14.21 and its 200-day moving average price is $12.97.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The company had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Russell Schundler sold 5,964 shares of the company's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares in the company, valued at approximately $7,738,984.57. This represents a 1.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Roger Jeffs sold 14,130 shares of Liquidia stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the sale, the chief executive officer now directly owns 1,006,420 shares of the company's stock, valued at approximately $13,657,119.40. This trade represents a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,138 shares of company stock worth $450,233. 30.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on LQDA. Needham & Company LLC reaffirmed a "buy" rating and issued a $25.00 price target on shares of Liquidia in a report on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. Finally, Scotiabank restated an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Co. (NASDAQ:LQDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.